Hertzel Gerstein

USPTO Granted Patents = 6 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 67(Granted Patents)

Location History:

Hamilton, CA (US) (2011)
Hamilton, CA (2008 - 2014)
Toronto, CA (2021 - 2023)

Company Filing History:

3 out of 207

Aventis Pharmaceuticals Inc.

patents

3 out of 1,829

Sanofi-a Ventis Deutschland Gmbh

where one patent can have more than one assignee

Years Active: 2008-2023

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11807905 - Growth differentiation factor 15 as biomarker for metformin (2023-11-07),

2. 10975434 - Growth differentiation factor 15 as biomarker for metformin (2021-04-13),

3. 8809270 - Method for reducing cardiovascular morbidity and mortality in prediaetic patients and patients with type 2 diabetes (2014-08-19),

4. 7977310 - Method for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes (2011-07-12),

5. 7405196 - Method for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes (2008-07-29),

6. 7368469 - Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events (2008-05-06),

Title: Innovations by Hertzel Gerstein in Cardiovascular Risk Assessment

Introduction

Hertzel Gerstein is an inventor based in Hamilton, Canada. He has made significant contributions to the field of cardiovascular health through his innovative research. His work focuses on the assessment of the risk for the development of cardiovascular disorders, which is a critical area of study given the increasing prevalence of heart-related diseases.

Latest Patent Applications

Hertzel Gerstein has filed a patent application titled "NEW MARKERS FOR THE ASSESSMENT OF THE RISK FOR DEVELOPMENT OF A CARDIOVASCULAR DISORDER." This invention relates to the use of biochemical markers in evaluating the risk of developing cardiovascular disorders. It also encompasses the use of these markers or marker panels for risk assessment and includes kits designed for performing the methods outlined in the invention.

Conclusion

Hertzel Gerstein's work in developing new markers for cardiovascular risk assessment represents a valuable contribution to medical science. His innovative approach has the potential to enhance the early detection and prevention of cardiovascular disorders, ultimately improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.